We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00752388
Recruitment Status : Completed
First Posted : September 15, 2008
Last Update Posted : November 19, 2013
Sponsor:
Information provided by:
Boehringer Ingelheim

Brief Summary:

To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by

  • determination of the prevalence of depression in PD patients, based on MDI severity categories and the self-rating scale WHO-5, where poor well being was indicated.
  • exploration of influencing factors (PD status, therapeutic status) on the prevalence of MDI depression categories.

Condition or disease
Parkinson Disease

Layout table for study information
Study Type : Observational
Actual Enrollment : 1588 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Application of the WHO-5 Well-being Index (WHO-5) as a Screening Instrument for Depression in Parkinson's Disease
Study Start Date : November 2008
Actual Primary Completion Date : November 2008

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Prevalence of patients with depressive symptoms (based on WHO-5 and MDI) in total and in subgroups [ Time Frame: day 1 ]

Secondary Outcome Measures :
  1. WHO-5 score and items [ Time Frame: day 1 ]
  2. MDI score (for a subgroup of patients with WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) [ Time Frame: day 1 ]
  3. Correlation of WHO-5 and MDI (for a subgroup of patients with a WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) in PD patients [ Time Frame: day 1 ]
  4. Investigator assessment of the applicability of the WHO-5 for screening for depression in PD patients [ Time Frame: day 1 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
resident physician
Criteria

Inclusion Criteria:

  1. PD patients attending one of the participating neurologist practices during 2 fixed weeks in November 2008
  2. Idiopathic PD with or without fluctuations
  3. Male or female PD patients aged at least 30
  4. Ability to reliably complete self-rating scales (WHO-5, MDI) ), according to the physician's judgement.
  5. Written informed consent by the patient for study participation.

Exclusion Criteria:

  1. PD Patients who only attend the practice to get a prescription and are not seen by the doctor on that day
  2. Patients who are not able to understand the questionnaires (e.g. due to mental impairment or language problems).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00752388


Locations
Show Show 278 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Layout table for additonal information
Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00752388    
Other Study ID Numbers: 248.658
First Posted: September 15, 2008    Key Record Dates
Last Update Posted: November 19, 2013
Last Verified: November 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases